<DOC>
	<DOC>NCT00160628</DOC>
	<brief_summary>A Korean open-label, community-based trial assessing the efficacy and safety of levetiracetam as adjunctive therapy in partial epilepsy. Similarity with a similar study conducted in Caucasian epileptic subjects will be assessed.</brief_summary>
	<brief_title>Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized. Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1. Use of one (1), but no more than two (2) concomitant marketed AEDs at the time of trial entry. Subjects on felbamate with less than 18 months exposure. Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months. Presence of known pseudoseizures within the last year. Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors. Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Keppra</keyword>
	<keyword>Levetiracetam</keyword>
</DOC>